“…3,5,17 Individual studies have also cited increasing dose per fraction, age > 55 years, increasing vertebral body tumor involvement, thoracolumbar junction and lumbar level metastases, tumor progression, lung and/or hepatocellular histology, solitary metastases, and lack of MRI for treatment planning as risk factors for VCF. 3,5,8,15,17,20 Variability in patient selection, fracture detection, presence of tumor, follow-up, and radiation methods may account for the wide range in the reported radiographic fracture risk and time to fracture. A paucity of data relates to the symptomatology of post-SRS VCF, with most of the above-mentioned studies reporting radiographic VCF progression rather than VCF-associated symptomatology.…”